ORCID Profile
0000-0001-8485-5150
Current Organisations
Royal Marsden Hospital
,
The Institute of Cancer Research
,
Università degli Studi della Calabria
,
Mayo Clinic Rochester
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
Fast and Accurate Video PQoS Estimation over Wireless Networks
Publisher: Springer Science and Business Media LLC
Date: 29-04-2008
DOI: 10.1155/2008/548741
Smart Wireless Access Networks and Systems for Smart Cities
Publisher: Elsevier BV
Date: 06-2016
Fast and Accurate PQoS Estimation over 802.11g Wireless Network
Publisher: IEEE
Date: 2008
DOI: 10.1109/ICC.2008.56
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association
Publisher: Springer Science and Business Media LLC
Date: 03-02-2021
DOI: 10.1038/S42003-020-01469-0
Abstract: Here we report the DNA methylation profile of 84 sporadic pancreatic neuroendocrine tumors (PanNETs) with associated clinical and genomic information. We identified three subgroups of PanNETs, termed T1, T2 and T3, with distinct patterns of methylation. The T1 subgroup was enriched for functional tumors and ATRX , DAXX and MEN1 wild-type genotypes. The T2 subgroup contained tumors with mutations in ATRX , DAXX and MEN1 and recurrent patterns of chromosomal losses in half of the genome with no association between regions with recurrent loss and methylation levels. T2 tumors were larger and had lower methylation in the MGMT gene body, which showed positive correlation with gene expression. The T3 subgroup harboured mutations in MEN1 with recurrent loss of chromosome 11, was enriched for grade G1 tumors and showed histological parameters associated with better prognosis. Our results suggest a role for methylation in both driving tumorigenesis and potentially stratifying prognosis in PanNETs.
The proteomic landscape of soft tissue sarcomas
Publisher: Springer Science and Business Media LLC
Date: 29-06-2201
DOI: 10.1038/S41467-023-39486-2
Abstract: Soft tissue sarcomas (STS) are rare and erse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological subtypes. Within leiomyosarcomas, we identify three proteomic subtypes with distinct myogenesis and immune features, anatomical site distribution and survival outcomes. Characterisation of undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas with low infiltrating CD3 + T-lymphocyte levels nominates the complement cascade as a candidate immunotherapeutic target. Comparative analysis of proteomic and transcriptomic profiles highlights the proteomic-specific features for optimal risk stratification in angiosarcomas. Finally, we define functional signatures termed Sarcoma Proteomic Modules which transcend histological subtype classification and show that a vesicle transport protein signature is an independent prognostic factor for distant metastasis. Our study highlights the utility of proteomics for identifying molecular subgroups with implications for risk stratification and therapy selection and provides a rich resource for future sarcoma research.
Related Organisations
Royal Marsden Hospital
Location: United Kingdom of Great Britain and Northern Ireland
The Institute Of Cancer Research
Location: United Kingdom of Great Britain and Northern Ireland
E O Lawrence Berkeley National Laboratory
Location: United States of America
Related Funding Activities
No related grants have been discovered for Anguraj Sadanandam.